GPC3 and hepatocellular carcinoma: Antibody-functionalized nanoparticles, such as those modified with anti-GPC3 antibodies, have demonstrated significant efficacy in delivering RNA molecules directly to HCC cells, allowing for targeted silencing of oncogenic pathways or activation of tumor suppressor genes.